PerSe Technologies News

CEO of Pluristem Therapeutics, Inc. tells shareholders that his firm's PLX cells may be effective in supporting bone marrow transplantation as well as other potential indications where bone marrow may be suppressed, such as radiation and chemotherapy.

Student Transportation : Stifel Nicolaus initiated coverage of this company with a rating of Buy and a price target of $7.3. Berry Petroleum : Barrington Research initiated coverage of this company with a rating of Outperform and a price target of $50. Forum Energy Tech.

The firm set a "buy" rating on the stock. Shares of Pluristem Therapeutics opened at 2.65 on Tuesday.

Recently , Pluristem Therapeutics' revealed preclinical data showing that its platform technology, PLX cells, is effective in a type of heart disease that has no current cures.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia HAIFA, Israel, May 15, 2012 -- Pluristem Therapeutics, Inc.

Pluristem Therapeutics +5.3% premarket after announcing cardiac function in pre-clinical diabetic diastolic heart failure subjects was improved by the use of the company's PLX cells.

As large pharmaceuticals face major patent expirations in 2012 they have looked to biotech companies to provide new streams of revenue.

U.S. consumer spending growth slowed in October and business capital investment plans were weak, raising questions about expectations for solid economic performance in the fourth quarter.

The companies whose shares are moving in pre-market trading on Friday are: Pluristem Therapeutics Inc, Mechel OAO, Zynga Inc, Pluristem Therapeutics Inc stock climbed 13.85 percent to $2.96 in pre-market trading.

HAIFA, Israel, May 9, 2012 -- Pluristem Therapeutics, Inc. /quotes/zigman/108591/quotes/nls/psti PSTI -4.53% today announced that a seven year-old girl suffering from an aplastic bone marrow whose condition was rapidly deteriorating is now experiencing a reversal of her condition with a significant increase in her red cells, white cells and ... (more)

David Blech, an investor who was known as the "King of Biotech" before he admitted to criminal charges of stock manipulation in 1998, has run into trouble with the law again over illegal trades in stocks of two biopharmaceutical companies.

Shares of Pluristem Therapeutics pop on the news that the use of the its PLacental eXpanded cells saved the life of a child, following a bone marrow transplant failure.

Shares of the following companies had unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 4 p.m. in New York.

SodaStream International Ltd. shares jump following first quarter results that easily beat consensus, plus a heightened guidance for 2012, as the company says that its decision to expand worldwide is affirmed by the figures.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia HAIFA, Israel, April 30, 2012 -- Pluristem Therapeutics Inc.